News
Scarlet Accelerates AI Medical Device Certification with $50M Investment
FundingOctober 15, 2026, 3:40 pm
Scarlet secured $50 million in Series B funding. This propels its global mission. The company aims to revolutionize AI medical device certification. Its AI-native platform dramatically cuts long regulatory timelines. This accelerates approvals for advanced, iterative healthcare AI. Scarlet uniquely holds designations from the EU, UK, and US FDA. It is the sole EU body focused purely on software and AI medical devices. This investment fuels rapid expansion across the US and Asia-Pacific. It ensures quicker, safer deployment of life-changing AI to patients. Healthcare innovation is now unblocked.
Scarlet, a pivotal player in medical technology, just closed a $50 million Series B funding round. This significant capital injection aims to reshape how AI medical devices achieve regulatory approval. Headline led the round. New investor Notion Capital joined. Existing investors Atomico, Creandum, Kindred Capital, and Entrepreneurs First also participated. Nancy Xiao McLaughlin, a partner at Headline, will now sit on Scarlet's board. The company's total funding approaches $75 million. This financial boost targets a critical bottleneck in modern healthcare: the slow pace of certification for rapidly evolving AI.
The medical device landscape is shifting dramatically. Artificial intelligence now powers diagnostics, clinical workflows, and various medical instruments. Yet, traditional regulatory pathways struggle to keep pace. Conventional certification bodies can take 12 to 18 months for initial market clearance. Even minor algorithmic updates face delays of six to eight months. Such long timelines stifle innovation. They prevent patients from accessing crucial technological advancements swiftly. AI models can be trained and validated in weeks. Certification processes often lag years behind. This disparity creates a chasm between development speed and market access.
Scarlet emerged to bridge this gap. Founded in London in 2021 by former Babylon Health AI engineers James Dewar and Jamie Cox, Scarlet spent its initial three years securing critical designations. It is not merely a consulting firm. Scarlet operates as a formal, government-designated statutory auditing and certification body. It holds unique designations. Under the EU Medical Device Regulation (EU MDR), Scarlet stands as the sole entity specializing exclusively in Software as a Medical Device (SaMD) and AI. This status is critical. It differentiates Scarlet from the approximately 52 other EU-designated bodies. Furthermore, Scarlet holds formal designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA). It can issue UKCA markings for medical software. The company is also recognized by the U.S. Food and Drug Administration (FDA) as a Third-Party Review Organization. This accreditation authorizes Scarlet to conduct substantive regulatory reviews for eligible 510(k) premarket notifications. These multiple designations solidify Scarlet's global authority in AI medical device certification.
The company's operating architecture modernizes technical file audits. Manufacturers upload clinical evaluation reports, verification and validation data, risk management files, and software architecture artifacts. These can be in any format. Scarlet’s AI-enabled platform parses and correlates this documentation against international harmonized standards. Specialized software and clinical AI reviewers conduct technical assessments. They evaluate machine learning architectures, training and testing distribution shifts, and cybersecurity controls. The process moves at software-native speed. Every audit finding, validation trace, and conformity decision is systematically evidenced. An immutable audit trail provides full visibility to regulatory bodies. This transparency fosters trust and efficiency.
Scarlet operates on a recurring enterprise subscription model. This covers ongoing post-market surveillance. It includes mandatory annual quality management system audits. It also supports continuous product changes. This framework allows manufacturers to clear bi-weekly model iterations and algorithmic updates. They avoid filing duplicative, multi-month re-submissions. This agile approach enables continuous integration and continuous deployment (CI/CD) pipelines for medical software. Companies like Flok Health, a digital physiotherapy platform, use Scarlet to deploy validated clinical updates twice per month. Such iteration velocity was previously unattainable under legacy European Notified Bodies. This means patients receive improved care faster.
Scarlet’s client roster demonstrates its broad impact. Leading digital health enterprises, consumer giants, acute health systems, and high-volume clinical AI providers leverage its platform. Flo Health, a women’s health application with over 500 million downloads, relies on Scarlet for regulatory certification. DeepHealth, a US radiology behemoth, utilizes it for acute enterprise imaging infrastructure. NHS England, a public institutional care infrastructure, also employs Scarlet’s services. Algorithmic oncology software specialists like Skin Analytics use the platform for cancer detection. Clinical voice and agentic documentation platforms, including ambient scribes Heidi Health and Tandem, are also clients. Both Heidi Health and Tandem recently secured nine-figure Series B financing rounds. These partnerships underscore the demand for faster, compliant AI certification.
This $50 million Series B injection fuels Scarlet's global expansion. The company will establish dedicated operational hubs across the United States. It will also build out its presence in the Asia-Pacific region. This move supports cross-border Software as a Medical Device (SaMD) clearance pipelines. Scarlet plans to expand its internal roster of specialized machine learning auditors. It will also recruit bio-engineers and regulatory clinicians. Furthermore, the company will broaden its certification portfolios. This expansion targets emergent multimodal foundation models, autonomous diagnostic agent frameworks, and generative clinical reasoning tools. Scarlet is building the infrastructure for the next generation of medical AI.
The integration of artificial intelligence into healthcare is accelerating. Diagnostics, treatment planning, and patient monitoring are all being transformed. However, the promise of AI depends on its safe and effective deployment. Regulatory bottlenecks have traditionally hindered this progress. Scarlet's AI-native approach removes these barriers. It ensures advanced medical technologies reach patients faster. The company's strategy aligns regulatory rigor with technological agility. It fosters innovation without compromising patient safety. This is critical for the future of digital health.
Scarlet is setting a new standard for AI medical device certification. Its unique platform and regulatory designations provide a crucial service. The $50 million funding round will solidify its leadership position. It will enable global scale and expanded capabilities. Healthcare stands on the cusp of an AI revolution. Scarlet ensures this revolution is both rapid and responsible. It champions patient access to life-changing technology. This investment marks a significant step towards a more innovative and responsive medical future.
Scarlet, a pivotal player in medical technology, just closed a $50 million Series B funding round. This significant capital injection aims to reshape how AI medical devices achieve regulatory approval. Headline led the round. New investor Notion Capital joined. Existing investors Atomico, Creandum, Kindred Capital, and Entrepreneurs First also participated. Nancy Xiao McLaughlin, a partner at Headline, will now sit on Scarlet's board. The company's total funding approaches $75 million. This financial boost targets a critical bottleneck in modern healthcare: the slow pace of certification for rapidly evolving AI.
The medical device landscape is shifting dramatically. Artificial intelligence now powers diagnostics, clinical workflows, and various medical instruments. Yet, traditional regulatory pathways struggle to keep pace. Conventional certification bodies can take 12 to 18 months for initial market clearance. Even minor algorithmic updates face delays of six to eight months. Such long timelines stifle innovation. They prevent patients from accessing crucial technological advancements swiftly. AI models can be trained and validated in weeks. Certification processes often lag years behind. This disparity creates a chasm between development speed and market access.
Scarlet emerged to bridge this gap. Founded in London in 2021 by former Babylon Health AI engineers James Dewar and Jamie Cox, Scarlet spent its initial three years securing critical designations. It is not merely a consulting firm. Scarlet operates as a formal, government-designated statutory auditing and certification body. It holds unique designations. Under the EU Medical Device Regulation (EU MDR), Scarlet stands as the sole entity specializing exclusively in Software as a Medical Device (SaMD) and AI. This status is critical. It differentiates Scarlet from the approximately 52 other EU-designated bodies. Furthermore, Scarlet holds formal designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA). It can issue UKCA markings for medical software. The company is also recognized by the U.S. Food and Drug Administration (FDA) as a Third-Party Review Organization. This accreditation authorizes Scarlet to conduct substantive regulatory reviews for eligible 510(k) premarket notifications. These multiple designations solidify Scarlet's global authority in AI medical device certification.
The company's operating architecture modernizes technical file audits. Manufacturers upload clinical evaluation reports, verification and validation data, risk management files, and software architecture artifacts. These can be in any format. Scarlet’s AI-enabled platform parses and correlates this documentation against international harmonized standards. Specialized software and clinical AI reviewers conduct technical assessments. They evaluate machine learning architectures, training and testing distribution shifts, and cybersecurity controls. The process moves at software-native speed. Every audit finding, validation trace, and conformity decision is systematically evidenced. An immutable audit trail provides full visibility to regulatory bodies. This transparency fosters trust and efficiency.
Scarlet operates on a recurring enterprise subscription model. This covers ongoing post-market surveillance. It includes mandatory annual quality management system audits. It also supports continuous product changes. This framework allows manufacturers to clear bi-weekly model iterations and algorithmic updates. They avoid filing duplicative, multi-month re-submissions. This agile approach enables continuous integration and continuous deployment (CI/CD) pipelines for medical software. Companies like Flok Health, a digital physiotherapy platform, use Scarlet to deploy validated clinical updates twice per month. Such iteration velocity was previously unattainable under legacy European Notified Bodies. This means patients receive improved care faster.
Scarlet’s client roster demonstrates its broad impact. Leading digital health enterprises, consumer giants, acute health systems, and high-volume clinical AI providers leverage its platform. Flo Health, a women’s health application with over 500 million downloads, relies on Scarlet for regulatory certification. DeepHealth, a US radiology behemoth, utilizes it for acute enterprise imaging infrastructure. NHS England, a public institutional care infrastructure, also employs Scarlet’s services. Algorithmic oncology software specialists like Skin Analytics use the platform for cancer detection. Clinical voice and agentic documentation platforms, including ambient scribes Heidi Health and Tandem, are also clients. Both Heidi Health and Tandem recently secured nine-figure Series B financing rounds. These partnerships underscore the demand for faster, compliant AI certification.
This $50 million Series B injection fuels Scarlet's global expansion. The company will establish dedicated operational hubs across the United States. It will also build out its presence in the Asia-Pacific region. This move supports cross-border Software as a Medical Device (SaMD) clearance pipelines. Scarlet plans to expand its internal roster of specialized machine learning auditors. It will also recruit bio-engineers and regulatory clinicians. Furthermore, the company will broaden its certification portfolios. This expansion targets emergent multimodal foundation models, autonomous diagnostic agent frameworks, and generative clinical reasoning tools. Scarlet is building the infrastructure for the next generation of medical AI.
The integration of artificial intelligence into healthcare is accelerating. Diagnostics, treatment planning, and patient monitoring are all being transformed. However, the promise of AI depends on its safe and effective deployment. Regulatory bottlenecks have traditionally hindered this progress. Scarlet's AI-native approach removes these barriers. It ensures advanced medical technologies reach patients faster. The company's strategy aligns regulatory rigor with technological agility. It fosters innovation without compromising patient safety. This is critical for the future of digital health.
Scarlet is setting a new standard for AI medical device certification. Its unique platform and regulatory designations provide a crucial service. The $50 million funding round will solidify its leadership position. It will enable global scale and expanded capabilities. Healthcare stands on the cusp of an AI revolution. Scarlet ensures this revolution is both rapid and responsible. It champions patient access to life-changing technology. This investment marks a significant step towards a more innovative and responsive medical future.